SUVEN LIFE SCIENCES LTD. - 530239 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
With reference to above subject, please find enclosed herewith an invitation for conducting the conference call for investors on Monday, May 27, 2019 at 12:00 noon IST to discuss the Audited Financial Results for the Q4 Financial Year 2019, to be declared on 25th May, 2019. Suven Life Sciences Ltd - 530239 - Board Meeting Intimation for Results For The Fourth Quarter And For The Year Ended March 31, 2019
SUVEN LIFE SCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2019 ,inter alia, to consider and approve the Audited Financial Results (Standalone and Consolidated) of the Company under Ind AS for the fourth quarter and for the year ended March 31, 2019 and related matters. Suven Life Sciences Ltd - 530239 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received intimation from our RTA dtd. 14-05-2019 regarding issued duplicate share certificate(s) in lieu of the loss of original share certificate(s) to the following shareholders(s). Suven Life Sciences Ltd - 530239 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompaySUVEN LIFE SCIENCES LTD. 2CININE495B01038 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: K. Hanumantha Rao Designation: Company Secretary EmailId: khrao@suven.com Name of the Chief Financial Officer: P. Subba Rao Designation: Chief Financial Officer EmailId: psrao@suven.com Date: 03/05/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Suven Life Sciences Ltd - 530239 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Suven completes the purchase of assets of Rising Pharmaceuticals through its joint venture partner, Shore Suven Pharma Inc. Suven Life Sciences Ltd - 530239 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received intimation from our RTA dtd. 17-04-2019 regarding issue of duplicate share certificate(s) in lieu of the loss of original share certificate(s) from the following shareholders(s). Suven Life Sciences Ltd - 530239 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the Company has received intimation from our RTA (Karvy Fintech Private Limited) regarding loss of share certificate(s) from the following shareholders(s). A copy of intimation from RTA is enclosed herewith. Suven Life Sciences Ltd - 530239 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 041401 Name of the Signatory :- K. Hanumantha RaoDesignation :- Company Secretary and Compliance Officer SUVEN LIFE SCIENCES LTD. - 530239 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (LODR) Regulations, 2015 For The Half-Year Ended 31St March, 2019
With reference to the above subject, please find enclosed compliance certificate for the half-year ended 31st March, 2019 duly signed by the Compliance Officer and authorised representative of the share transfer agent (Karvy Fintech Pvt. Ltd., Hyderabad), under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We request you to take this document on your record. SUVEN LIFE SCIENCES LTD. - 530239 - Shareholding for the Period Ended March 31, 2019
Suven Life Sciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here